Post #118 describes the usual case. This is about the unusual one.
Obstructive sleep apnoea would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Post #118 describes the usual case. This is about the unusual one.
Obstructive sleep apnoea would be much easier to settle if anyone reported the denominator. Almost nobody reports the denominator.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
If this contradicts something upthread, the upthread version may well be the better one.
PCOS and metabolic overlap: polycystic ovary syndrome has metabolic overlap with obesity and insulin resistance. Data on compounds in this class in PCOS specifically is thin; most discussion is by mechanism.
Not the answer, but possibly the question that gets there.
An update on my earlier obstructive sleep apnoea post: the pattern held for another six weeks and then stopped, which I did not predict and cannot explain.
The arithmetic in post #125 is right; the assumption feeding it is the part to check.
Obstructive sleep apnoea: SURMOUNT-OSA used an objective endpoint, the apnoea-hypopnoea index. Reduction was substantial. Whether the benefit is weight loss or a direct drug effect is not resolved by the trial.
Comorbidity control: if a comorbidity (high blood pressure, high lipids) is not adequately controlled, the decision about adding compounds in this class depends on the current control status, not on the compound alone.
It took me longer than it should have to see that.
Obstructive sleep apnoea sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Renal function affects clearance for some compounds in this class and not others. The published data is compound-specific and is worth checking rather than generalising.
If that is already documented somewhere, ignore me and link it.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class
Second pass at: Obstructive sleep apnoea and a hard endpoint in this class — setting out what I have, and where I think it stops being reliable. Something about Obstructive sleep apnoea does not reconcile and…
|
2 | 726 | 14mo | |
|
Hepatic steatosis: what the MASH trial evidence supports
Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on hepatic steatosis, before…
|
+77 | 83 | 950 | 13mo |
|
Hypertension improvement and when medication needs revisiting — a second dataset
Posting this under the heading it deserves: Hypertension improvement and when medication needs revisiting — a second dataset Everything below is what sits behind that. Posting a small dataset on Hypertension…
|
+126 | 133 | 22k | 21mo |
|
Heart failure with preserved ejection fraction: symptom endpoints
Heart failure with preserved ejection fraction: symptom endpoints — setting out what I have, and where I think it stops being reliable. Heart failure with preserved ejection keeps being re-asked here and I…
|
+19 | 23 | 311 | 12d |
|
[2026 update] Gastro-oesophageal reflux: improving or worsening?
Asking directly, because I could not find a straight answer: Gastro-oesophageal reflux: improving or worsening? Gastro-oesophageal reflux — I have the observation and I do not trust my interpretation of it,…
|
3 | 782 | 13mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Comorbidities category
Type 2 diabetes, hepatic steatosis, sleep apnoea, cardiovascular and renal disease. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author…
|
4 | 16k | 12h | |
|
How much fluid is actually needed, and how you would know
The question in the title: How much fluid is actually needed, and how you would know I will give what I have already checked below so nobody repeats it. Reporting what I changed and what happened, with the…
|
+11 | 15 | 53k | 2mo |
|
Injection timing and sleep disruption — the long version
Injection timing and sleep disruption — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about Injection timing and sleep disruption, deliberately…
|
2 | 164 | 16mo | |
|
Second pass at: Pregnancy and pregnancy planning: contraindication and washout
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Writing it up because I had to work it out twice and would rather nobody else did. Something about Pregnancy and pregnancy…
|
+111 | 127 | 1.6k | 6mo |
|
Adolescents: a distinct evidence base
Adolescents: a distinct evidence base Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of adolescents is wrong? I ask because I have been…
|
3 | 11k | 9h |